Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid

BMJ Case Rep. 2024 Nov 28;17(11):e262628. doi: 10.1136/bcr-2024-262628.

Abstract

A patient with a long history of bone predominant, metastatic paraganglioma who had multiple episodes of progressive disease despite prior treatments demonstrated a remarkable disease response to zoledronic acid. After 1 year of treatment, there was a complete resolution of lymphadenopathy and disappearance of all somatostatin receptor avid lesions by positron emission tomography-CT and radiopharmaceutical Gallium Ga 68 Dotatate. Stability of disease was further demonstrated by CT over several years. The patient continues on surveillance.

Keywords: Calcium and bone; Cancer - see Oncology; Cancer intervention; Oncology; Therapeutic indications.

Publication types

  • Case Reports

MeSH terms

  • Bone Density Conservation Agents* / therapeutic use
  • Bone Neoplasms* / diagnostic imaging
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / secondary
  • Diphosphonates / therapeutic use
  • Humans
  • Imidazoles* / therapeutic use
  • Middle Aged
  • Paraganglioma* / diagnostic imaging
  • Paraganglioma* / drug therapy
  • Paraganglioma* / secondary
  • Positron Emission Tomography Computed Tomography
  • Remission Induction
  • Zoledronic Acid* / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid